Ergocalciferol in Chronic Kidney Disease

Saint Louis VA Medical Center

Overview

To examine the effect of ergocalciferol treatment on 25-hydroxyvitamin D and PTH levels in patients with CKD stage 3 and 4

Study Type

OBSERVATIONAL

Conditions

Chronic Kidney Disease

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient with CKD stage 3 or 4 whose 25-hydroxyvitamin D levels are below 30 ng/ml and plasma intact PTH levels \>70 pg/ml. Exclusion Criteria: * Patients who are on any form of active vitamin treatment

Locations (1)

Saint Louis VA Medical Center

St Louis, Missouri, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.